High-Risk Stages II and III Colon Cancer: 3 Versus 6 Months of Adjuvant Therapy
Posted: Wednesday, August 7, 2019
According to findings presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 3500) and published in the Journal of Clinical Oncology, 3-year disease-free survival rates for patients diagnosed with high-risk stage II and stage III colon cancer depend upon the administered adjuvant regimen. These findings, from the Hellenic Oncology Research Group and the International Duration Evaluation of Adjuvant Chemotherapy project, indicate the correct regimen and duration of adjuvant chemotherapy should be personalized for each patient, concluded Ioannis Sougklakos, MD, of the University of Heraklion, Greece, and colleagues.
In this clinical trial, the investigators enrolled 1,121 patients diagnosed with high-risk stage II (413 patients) and stage III colon cancer (708 patients). The patients were assigned either 3 months or 6 months of oxaliplatin, leucovorin, and fluorouracil (FOLFOX4) or capecitabine plus oxaliplatin (CAPOX) therapy.
After a median follow-up of 67 months, 79 disease-free survival events occurred among the patients diagnosed with high-risk stage II disease (43 in the 3-month group and 38 in the 6-month group), resulting in 3-year disease-free survival rates of 82.7% and 83.4%, respectively. Among the patients with stage III disease, 214 disease-free survival events occurred (161 in the 3-month cohort and 153 in the 6-month cohort), for a 3-year disease-free survival rate of 72.9% and 74.1%, respectively.
For the patients with stage II disease treated with FOLFOX4, 3-year disease-free survival rates were 76.7% for those treated for 3 months, compared with 79.3% for those treated for 6 months. Patients with stage II disease who received CAPOX had 3-year disease-free survival rates of 85.4% and 83.8% in the 3- and 6-month cohorts, respectively. Among those with diseasestage III patients, 3-year disease-free survival rates were 71.5% and 77.3% in the 3- and 6-month groups, respectively, after being treated with modified FOLFOX6 and 74.5% and 74.7%, respectively, after being treated with CAPOX.
Disclosure: The study authors’ disclosure information may be found at coi.asco.org.